RESUMEN
BACKGROUND: Coronary intravascular lithotripsy (IVL) is an emerging therapy for the modification of coronary artery calcification (CAC). Data on its use in several clinical and lesion subsets are limited due to their exclusion from preapproval trials. METHODS: We performed a retrospective review of patients who were excluded from preapproval trials of coronary IVL and underwent CAC modification with the off-label use of a peripheral IVL system. The primary outcome was a composite of procedural success, defined as residual stenosis <10%, and no major adverse cardiac event (MACE), ie, cardiac death, myocardial infarction, or target- vessel revascularization, in hospital and at 30 days. RESULTS: Between June 2019 and April 2020, a total of 9 patients who underwent off-label coronary IVL were identified. Exclusion criteria from preapproval trials included a target lesion within an unprotected left main coronary artery (ULMCA; n = 3) and/or ostial location (n = 5), a target lesion involving in-stent restenosis (n = 3), a second target-vessel lesion with >50% stenosis (n = 1), and/or New York Heart Association class III/IV heart failure (n = 5). The primary outcome was achieved in 8 patients. MACE rate was 0% in hospital and at 30 days. For ULMCA lesions (n = 3), residual stenosis was 0% in 2 patients and 10% in 1 patient. For right coronary artery lesions (n = 3), residual stenosis was 0% in 2 patients and 40% in 1 patient. For left anterior descending coronary artery lesions (n = 3), residual stenosis was 0% in all patients. CONCLUSION: Coronary IVL with a peripheral IVL system may be an effective therapy for CAC modification within ULMCA disease, ostial disease, in-stent restenosis, and New York Heart Association class III/IV heart failure.
Asunto(s)
Enfermedad de la Arteria Coronaria , Litotricia , Calcificación Vascular , Enfermedad de la Arteria Coronaria/diagnóstico , Enfermedad de la Arteria Coronaria/cirugía , Humanos , Estudios Retrospectivos , Stents , Resultado del Tratamiento , Calcificación Vascular/diagnóstico , Calcificación Vascular/terapiaRESUMEN
BACKGROUND: Microvascular obstruction (MO) is a pathophysiologic complication of acute myocardial infarction that portends poor prognosis; however, it is transient and disappears with infarct healing. Much remains unknown regarding its pathophysiology and whether there are predictors of MO that could function as stable surrogates. We tested for clinical and cardiovascular magnetic resonance predictors of MO to gain insight into its pathophysiology and to find a stable surrogate. METHODS: Three hundred two consecutive patients from 2 centers underwent cardiovascular magnetic resonance within 2 weeks of first acute myocardial infarction. Three measures of infarct morphology: infarct size, transmurality, and a new index-the epicardial surface area (EpiSA) of full-thickness infarction-were quantified on delayed-enhancement cardiovascular magnetic resonance. RESULTS: Considering all clinical characteristics, only measures of infarct morphology were independent predictors of MO. EpiSA was the strongest predictor of MO and provided incremental predictive value beyond that of infarct size and transmurality (P<0.0001). In patients with 3-month follow-up cardiovascular magnetic resonance (n=81), EpiSA extent remained stable while MO disappeared, and EpiSA was a predictor of adverse ventricular remodeling. After 20 months of follow-up, 11 died and 1 had heart transplantation. Patients with an EpiSA larger than the median value (≥6%) had worse outcome than those with less than the median value (adverse events: 6.4% versus 1.9%, P=0.045). CONCLUSIONS: The EpiSA of infarction is a novel index of infarct morphology which accurately predicts MO during the first 2 weeks of MI, but unlike MO, does not disappear with infarct healing. This index has potential as a stable surrogate of the presence of acute MO and may be useful as a predictor of adverse remodeling and outcome which is less dependent on the time window of patient assessment.
Asunto(s)
Circulación Coronaria/fisiología , Vasos Coronarios/diagnóstico por imagen , Imagen por Resonancia Cinemagnética/métodos , Infarto del Miocardio/diagnóstico , Pericardio/diagnóstico por imagen , Remodelación Ventricular , Vasos Coronarios/fisiopatología , Electrocardiografía , Femenino , Humanos , Masculino , Microcirculación/fisiología , Persona de Mediana Edad , Infarto del Miocardio/fisiopatologíaRESUMEN
Functional mitral regurgitation (FMR) is common in patients with heart failure and portends a poor prognosis. The etiology is secondary to nonischemic or ischemic (postmyocardial infarction) adverse remodeling. Treatment includes guideline-directed medical therapy, cardiac resynchronization therapy, and in some cases, surgical repair or replacement. Transcatheter mitral valve (MV) repair with the MitraClip device is approved in patients with degenerative MR and is currently under investigation for use in FMR, as are several transcatheter MV replacement devices. This review discusses the basis of FMR pathophysiology, classification, and prognosis; provides an overview of current therapeutic approaches; examines the available literature on the use of MitraClip in patients with FMR; and provides insight into ongoing clinical trials and new investigational devices for the treatment of FMR.
Asunto(s)
Cardiólogos , Implantación de Prótesis de Válvulas Cardíacas/métodos , Insuficiencia de la Válvula Mitral/etiología , Isquemia Miocárdica/complicaciones , Humanos , Insuficiencia de la Válvula Mitral/cirugía , PronósticoAsunto(s)
Función del Atrio Izquierdo , Presión Atrial , Cateterismo Cardíaco/instrumentación , Implantación de Prótesis de Válvulas Cardíacas/instrumentación , Prótesis Valvulares Cardíacas , Insuficiencia de la Válvula Mitral/cirugía , Válvula Mitral/cirugía , Monitoreo Intraoperatorio/métodos , Cateterismo Cardíaco/métodos , Catéteres Cardíacos , Estudios de Factibilidad , Implantación de Prótesis de Válvulas Cardíacas/métodos , Humanos , Válvula Mitral/diagnóstico por imagen , Válvula Mitral/fisiopatología , Insuficiencia de la Válvula Mitral/diagnóstico por imagen , Insuficiencia de la Válvula Mitral/fisiopatología , Valor Predictivo de las Pruebas , Factores de TiempoRESUMEN
OBJECTIVES: The purpose of this study was to assess the performance of cardiac magnetic resonance (CMR) methods for discriminating acute from chronic myocardial infarction (MI). BACKGROUND: Although T2-weighted CMR is thought to be accurate in differentiating acute from chronic MI, few studies have reported on diagnostic accuracy, and these generally compared extremes in infarct age (e.g., <1 week old vs. more than 6 months old) and did not evaluate other CMR methods that could be informative. METHODS: A total of 221 CMR studies were performed at various time points after ST-segment elevation myocardial infarction in 117 consecutive patients without a history of MI or revascularization enrolled prospectively at 2 centers. Imaging markers of acute MI (<1 month) were T2 hyperintensity on double inversion recovery turbo spin echo (DIR-TSE) images, microvascular obstruction (MO) on delayed-enhancement CMR, and focally increased end-diastolic wall thickness (EDWT) on cine-CMR. RESULTS: The prevalence of T2-DIR-TSE hyperintensity decreased with infarct age but remained substantial up to 6 months post-MI. In contrast, the prevalence of both MO and increased EDWT dropped sharply after 1 month. T2-DIR-TSE sensitivity, specificity, and accuracy for identifying acute MI were 88%, 66%, and 77% compared with 73%, 97%, and 85%, respectively, for the combination of MO or increased EDWT. On multivariable analysis, persistence of T2-hyperintensity in intermediate-age infarcts (1 to 6 months old) was predicted by larger infarct size, diabetes, and better T2-DIR-TSE image quality score. For infarct size ≥ 10% of the left ventricle, a simple algorithm incorporating all CMR components allowed classification of infarct age into 3 categories (<1 month old, 1 to 6 months old, and ≥ 6 months old) with 80% (95% confidence interval: 73% to 87%) accuracy. CONCLUSIONS: T2-DIR-TSE hyperintensity is specific for infarcts <6 months old, whereas MO and increased EDWT are specific for infarcts <1 month old. Incorporating multiple CMR markers of acute MI and their varied longevity leads to a more precise assessment of infarct age.
Asunto(s)
Ventrículos Cardíacos/patología , Imagen por Resonancia Cinemagnética/métodos , Infarto del Miocardio/diagnóstico , Enfermedad Aguda , Enfermedad Crónica , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Factores de TiempoRESUMEN
PURPOSE: To compare the utility and efficacy of stress cardiac magnetic resonance (MR) imaging and stress echocardiography in an emergency setting in patients with acute chest pain (CP) and intermediate risk of coronary artery disease (CAD). MATERIALS AND METHODS: Written informed consent was obtained from all patients. This HIPAA-compliant study was approved by the institutional review board for research ethics. Sixty patients without history of CAD presented to the emergency department with intermediate-risk acute CP and were prospectively enrolled. Patients underwent both stress cardiac MR imaging and stress echocardiography in random order within 12 hours of presentation. Stress imaging results were interpreted clinically immediately (blinded interpretation was performed months later), and coronary angiography was performed if either result was abnormal. CAD was considered significant if it was identified at angiography (narrowing >50% ) or if a cardiac event (death or myocardial infarction) occurred during follow-up (mean, 14 months ± 5 [standard deviation]). McNemar test was used to compare the diagnostic accuracy of techniques. RESULTS: Stress cardiac MR imaging and stress echocardiography had similar specificity, accuracy, and positive and negative predictive values (92% vs 96%, 93% vs 88%, 67% vs 60%, and 100% vs 91%, respectively, for clinical interpretation; 90% vs 92%, 90% vs 88%, 58% vs 56%, and 98% vs 94%, respectively, for blinded interpretation). Stress cardiac MR imaging had higher sensitivity at clinical interpretation (100% vs 38%, P = .025), which did not reach significance at blinded interpretation (88% vs 63%, P = .31). However, multivariable logistic regression analysis showed stress cardiac MR imaging to be the strongest independent predictor of significant CAD (P = .002). CONCLUSION: In patients presenting to the emergency department with intermediate-risk CP, adenosine stress cardiac MR imaging performed within 12 hours of presentation is safe and potentially has improved performance characteristics compared with stress echocardiography. Online supplemental material is available for this article.
Asunto(s)
Dolor en el Pecho/diagnóstico , Enfermedad Coronaria/diagnóstico , Ecocardiografía de Estrés , Servicio de Urgencia en Hospital , Imagen por Resonancia Magnética/métodos , Dolor en el Pecho/diagnóstico por imagen , Dolor en el Pecho/fisiopatología , Medios de Contraste , Angiografía Coronaria , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Compuestos Organometálicos , Valor Predictivo de las Pruebas , Medición de Riesgo , Factores de Riesgo , Sensibilidad y EspecificidadRESUMEN
This article focuses on delayed contrast enhanced MRI (DE-MRI) to assess myocardial viability. We start by discussing previous literature that evaluated the potential importance of myocardial viability testing and follow up with the more recent Surgical Treatment for Heart Disease Trial (STICH) trial results. We then provide an overview of the basic concepts and technical aspects of the current DE-MRI technique and review the initial studies demonstrating that DE-MRI before coronary revascularization can predict functional improvement. Finally, we use DE-MRI as a paradigm to discuss physiological insights into viability assessment and examine common assumptions in the metrics used to evaluate viability techniques.